New ventilation strategy aims to reduce lung damage in severe pneumonia

NCT ID NCT07679802

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests a new way of using a breathing machine (ventilator) called time-controlled adaptive ventilation (TCAV) in people with severe lung injury from pneumonia. The goal is to see if TCAV reduces fluid buildup in the lungs compared to standard ventilation. The trial involves 56 adults in the intensive care unit who need a breathing machine. If TCAV works, it could lead to better outcomes and fewer complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Time-controlled adaptive ventilation (TCAV) using Airway Pressure Release Ventilation mode
What this could lead to
If effective, TCAV could offer a simple, low-cost way to reduce lung injury and improve survival in patients with severe respiratory failure.
What could go wrong
This is a small pilot study with 56 participants, so results may not apply broadly. The new ventilation method could also cause harm, such as worsening oxygen levels or kidney problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARDS (ACUTE RESPIRATORY DISTRESS SYNDROME) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHRU de Nancy

    Nancy, 54000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.